Comparative effectiveness analysis of survival with first-line palbociclib or ribociclib plus AI in HR + /HER2- advanced breast cancer (CEPRA study): preliminary analysis of real-world data from Thailand
比较帕博西尼或瑞博西尼联合AI治疗HR+/HER2-晚期乳腺癌患者的生存疗效（CEPRA研究）：来自泰国的真实世界数据的初步分析
期刊:BMC Cancer
影响因子:3.4
doi:10.1186/s12885-024-12765-x
Dajsakdipon, Thanate; Susiriwatananont, Thiti; Wongkraisri, Concord; Ithimakin, Suthinee; Parinyanitikul, Napa; Supavavej, Archara; Dechaphunkul, Arunee; Sunpaweravong, Patrapim; Neesanun, Sunee; Akewanlop, Charuwan; Dejthevaporn, Thitiya
